A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57)
Publication
, Conference
Ross, HJ; Kozono, DE; Mix, MD; Urbanic, JJ; Williams, TM; O'Donnell, T; Bara, I; Schulze, K; Wang, XF; Nelson, GD; Stinchcombe, T
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Ross, H. J., Kozono, D. E., Mix, M. D., Urbanic, J. J., Williams, T. M., O’Donnell, T., … Stinchcombe, T. (2024). A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Ross, Helen J., David E. Kozono, Michael D. Mix, James John Urbanic, Terence Marques Williams, Taylor O’Donnell, Ilze Bara, et al. “A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Ross HJ, Kozono DE, Mix MD, Urbanic JJ, Williams TM, O’Donnell T, et al. A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57). In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Ross, Helen J., et al. “A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Ross HJ, Kozono DE, Mix MD, Urbanic JJ, Williams TM, O’Donnell T, Bara I, Schulze K, Wang XF, Nelson GD, Stinchcombe T. A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57). JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis